Approved labelTERLIVAZ prescribing information for hepatorenal syndrome with rapid reduction in kidney function
PopulationAdults covered by the approved TERLIVAZ indication
Dose0.85 mg by intravenous injection every 6 hours on days 1 through 3, followed by label-directed adjustment on day 4 based on serum creatinine change
RouteIntravenous injection through a peripheral or central line
FrequencyEvery 6 hours with label-directed reassessment and adjustment
DurationContinue until 24 hours after two consecutive qualifying serum creatinine values or for a maximum of 14 days
PreparationReconstitute each 0.85 mg vial with 5 mL of 0.9% Sodium Chloride Injection to make 0.85 mg/5 mL. Refrigerated reconstituted solution may be stored for up to 48 hours; do not freeze.